Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) | MicrobiomeTrials← Back to trialsNCT07631637
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-07-15Est. Completion: 2029-02-06
Enrollment target: 150 participants Other microbiome trials you might be interested in
Non-alcoholic Fatty Liver Disease
This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in pa…
Rialto, United StatesEst. completion Oct 13, 2027
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
The newly adapted definition for MASLD includes evidence for hepatic steatosis by imaging or biopsy with at least one of…
Sohag, EgyptEst. completion Jan 1, 2027